Methylphenidate for ADHD
Trial Summary
What is the purpose of this trial?
This trial studies how methylphenidate affects brain activity and chemicals in adults with ADHD using brain scans. The goal is to develop better treatments for ADHD. Methylphenidate is the most common treatment for attention deficit hyperactivity disorder (ADHD) and has been shown to improve attention and behaviour.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
What evidence supports the effectiveness of the drug Methylphenidate for treating ADHD?
Research shows that controlled-delivery methylphenidate, like Metadate CD, is effective in reducing ADHD symptoms in children and adolescents, performing better than a placebo and similarly to immediate-release versions. Additionally, dexmethylphenidate, a form of methylphenidate, has been found effective at managing ADHD symptoms at lower doses.12345
Is methylphenidate generally safe for humans?
How is the drug Methylphenidate unique in treating ADHD?
Methylphenidate, especially in its controlled-delivery form (like Metadate CD), is unique because it provides effective symptom control throughout the school day with just one dose, making it convenient for children and adolescents with ADHD. It is also well-tolerated and can be used alongside behavioral and psychosocial interventions.134610
Research Team
Kristin L Bigos, PhD
Principal Investigator
Johns Hopkins School of Medicine
Eligibility Criteria
This trial is for right-handed adults with ADHD who can undergo MRI scans. It's not suitable for those with cognitive issues not due to ADHD, contraindications to MRI, pregnancy, breastfeeding, current smokers, history of bad reactions to stimulants like methylphenidate, uncontrolled medical conditions or past/current neurological disorders.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive a single oral dose of methylphenidate or placebo, followed by neuropsychological testing and fMRI/MRS scans
Washout
A washout period of one week between treatments to clear the previous dose
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Methylphenidate
- Placebo
Methylphenidate is already approved in United States, Canada, European Union for the following indications:
- Attention Deficit Hyperactivity Disorder (ADHD)
- Narcolepsy
- Attention Deficit Hyperactivity Disorder (ADHD)
- Narcolepsy
- Attention Deficit Hyperactivity Disorder (ADHD)
- Narcolepsy
Find a Clinic Near You
Who Is Running the Clinical Trial?
Johns Hopkins University
Lead Sponsor
National Institutes of Health (NIH)
Collaborator